Merrill maintains Amgen at buy

Amgen Inc. was maintained at buy with a $104 price objective by Merrill Lynch analyst Eric Ende after the company filed a suit in the U.S. District Court of Boston alleging that the launch of Roche's CERA would infringe on Amgen's EPO patents. Amgen received a favorable judgment in the court last year in a previous patent infringement case, and Ende said Amgen may have the upper hand in the current litigation. Shares of the Thousand Oaks, Calif.-based biotechnology company were up $1.59, or 1.98%, at $81.81 on volume of 7,697,538 shares versus the three-month running average of 8,442,710 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.